1. Bronchial asthma affects:
a. lung parenchyma 
b. bronchi*
c. bronchi and lung parenchyma

2. Atopic bronchial asthma is often preceded by:
a. urticaria
b. food allergy
c. allergic rhinitis*
d. contact allergic dermatitis

3. Which blood cells are essential for maintaining chronic inflammation in bronchial asthma:
a. macrophages
b. T-cytotoxic lymphocytes
c. eosinophils*
d. mast cells

4. Which of the following groups of drugs are not used in treating bronchial asthma:
a. inhaled corticosteroids
c. inhaled beta 2 agonists
v. antihistamines*
e. leukotriene antagonists

5. The bronchial hyperreactivity characteristic of patients with bronchial asthma is due to:
a. bronchospasm provoked by non-specific irritants such as cold air, strong odors, etc.*
b. bronchospasm provoked by minimal amounts of allergen
c. disturbance of bronchial mucociliary clearance
d. frequent bronchospasm at night

6. Bronchial hyperreactivity characteristic of patients with bronchial asthma is due to:
a. besquamation of the bronchial epithelium caused by chronic eosinophilic inflammation*
b. increased tone to n. vagus
c. increased muscarinic receptor activity
d. increased activity of H1 receptors

7. The bronchodilator test shall be performed:
a. in patients with reduced spirometry and changes in physical lung status*
b. in asymptomatic patients with normal spirometry and history of cough and shortness of breath
c. for monitoring the conducted therapy
d. to differentiate atopic from non-atopic bronchial asthma

8. The non-specific bronchial challenge test with methacholine is performed:
a. in patients with reduced spirometry and changes in physical lung status
b. in asymptomatic patients with normal spirometry and history of cough and shortness of breath*
c. for monitoring the conducted therapy
d. to differentiate atopic from non-atopic bronchial asthma

9. Obstructive type of spirometry is:
a. FEV1, PEF and FVC are reduced, Tifno's index is normal
b. FEV1, PEF and Tifno Index are reduced, FVC does not change*
c. FEV1, PEF, FVC and the Tifno index have been reduced
d. FEV1, PEF, FVC and Tifno index are between 80-90%

10. Which of the following groups of drugs affect the allergic inflammation ofpatients with bronchial asthma:
a. beta 2 prolonged-release agonists
b. inhaled corticosteroids*
c. beta 2 short-acting agonists
d. methylxanthine drugs (theophylline, novfillin)

11. Which group of drugs should not be used alone in the treatment of bronchial asthma:
a. methylxanthine drugs (theophylline, novphylline)
b. beta 2 agonists with prolonged action*
c. leukotriene antagonists
d. systemic corticosteroids

12. Bronchial asthma becomes chronic in:
a. COPD*
b. pulmonary fibrosis
c. cystic fibrosis
d. chronic bronchiolitis

13. Patients with bronchial asthma should not be treated with:
a. calcium antagonists
c. diuretics
s. beta blockers*
e. hydralazine

14. The peak expiratory flow(PEF) is:
a. the maximum speed of the exhaled air*
b. the maximum volume of exhaled air
c. the volume of exhaled air for the first second of expiration
d. 50% of the volume of exhaled air

15. TheclassificationofAllergicRhinitisaccordingto ARIA:
a. light, medium-heavyandheavy
b. acute, subacuteandchronic
c. viral, bacterial, pollen, causedbyhouseholdallergens
d. intermittent and persistent*

16. Allergicrhinitisofteniscombinedwith:
a. chronicurticaria
b. angioedemaintheeyelidarea
c. atopicbronchialasthma*
d. contactallergicdermatitis

17. The color and appearanceof patientsnasal mucosa suffering from allergic rhinitis with exacerbation of symptoms:
a. pale, livid, edematous*
b. erythema
c. thereisnochangeincolor
d. withoutchangeincolor, edematous

18.Allergenspecificimmunotherapywithhousedustmitesallergrnsinpatientswithallergicrhinitisshouldbestarted:
a. inthefall
b. inthespring
c.inthesummer
d. canstartinanyseason* 

19. Nasaldecongestants:
a. shouldnotbeusedinthetreatmentofallergicrhinitis
b. canusedonlyintheperiodofexacerbation, for nomorethan 3-5 days*
c. canbeusedfor a longtime

20. TheWilcoxtestispositiveat:
a. allergicrhinitis
b. bacterialrhinitis
c.viralrhinitis
d. inalltypesofrhinitis*

21. Inthenasalwashof a patientwithallergicrhinitisarefound:
a. neutrophils
b. eosinophils*
c.mastcells
d. segmentallymphocytes

22. Thepeakexpiratoryflow(PEF)is:
a. maximumexhaledairvelocity *
b. themaximumvolumeofexhaledair
c. thevolumeofexhaledairforthefirstsecondofexpiration
d. 50% ofthevolumeofexhaledair

23. FEV1 is:
a. the volume of exhaled air for the first second in forced expiration *
b. the maximum volume of exhaled air
c. the maximum velocity of the exhaled air

24. FVC is:
a. the maximum speed of exhaled air in forced expiration
b. the maximum volume of exhaled air in forced expiration *
c. the volume of exhaled air for the first second of expiration
d. 50% of the volume of exhaled air

25. Tifno's index is:
a. the ratio between FEV1 / FVC *
b. FVC / FEV1
c. PEF / FVC
d. PEF / FEV1

26. Obstructive type of spirometry is:
a. FEV1, PEF and FVC are reduced, Tifno's index is normal.
b. FEV1, PEF and Tifno Index are reduced, FVC does not change*
c. FEV1, PEF, FVC and the Tifno index have been reduced
d. FEV1, PEF, FVC and Tifno index are between 80-90%

27. The non-specific bronchial challenge test with methacholine is performed:
a. in patients with reduced spirometry and changes in physical lung status
b. in asymptomatic patients with normal spirometry and history of cough and shortness of breath*
c. for monitoring the conducted therapy
d. to differentiate atopic from non-atopic bronchial asthma

28.  The bronchodilator test shall be performed:
a. in patients with reduced spirometry and changes in physical lung status*
b. in asymptomatic patients with normal spirometry and history of cough and shortness of breath
c. for monitoring the conducted therapy
d. to differentiate atopic from non-atopic bronchial asthma

29. Thebronchodilatortestispositivewith a resultabove:
a. 10%
b.15%*
c.20%
d. 8%

30. Thenon-specificbronchialchallengetestwithmethacholineispositivein:
a. increaseoftheinitial FEV1 by 20%
b. reductionoftheinitial FEV1 by 20%*
c. increaseoftheinitial FEV1 by 10%
d. reductionoftheinitial FEV1 by 40%

31. Before performing a bronchodilator test, the patient should stop treatment with:
a. long-acting beta-2 agonists 12 hours before the test*
b. beta-2 blockers
c. antiarrhythmic drugs
e. calcium antagonists

32. Basicallyforthediagnosisofallergicrhinitisis:
a. medicalhistory
b. physicalexamination
c. skintestswithallergens*
d. computertomographyofnasalcavities

33. The Wilcox test is positive at:
a. allergic rhinitis
b. bacterial rhinitis
c. viral rhinitis
d. in all types of rhinitis*

34. In the nasal wash of a patient with allergic rhinitis are found:
a. neutrophils
b. eosinophils*
c. mast cells
d. segmental lymphocytes

35. Rhinomanometry is:
a. specific test for allergic rhinitis
b. a specific test for infectious rhinitis
c. test for each type of rhinitis*

36. When performing a nasal / conjunctival provocation test with allergens:
a. the patient may have symptoms of allergic rhinitis / conjunctivitis
b. the patient should be asymptomatic*
c. the clinical condition is not relevant to the test